TSCAN THERAPEUTICS INC TCRX
ASignal's systematic analysis rates TCRX as Bearish.
Reflects the latest available analysis · analyzed Nov 10, 2026
The case on TCRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Cash position exceeds total debt, indicating near-term liquidity
- Current ratio of 3.37x suggests ability to cover short-term obligations
- Price near lower Bollinger Band, indicating potential reversal signal
- Negative operating margin at -2901.33%, indicating severe operational losses
- Negative revenue growth of -65.80% year-over-year
- Negative return on equity (-95.80%) and return on assets (-31.53%)
- EV/EBITDA of -0.03x and forward P/E of -0.32x suggest unprofitability
- Free cash flow of -$79.92M indicates significant cash burn
- MACD below signal line and negative price momentum
See the full verdict on TCRX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TCRX
Most investors never get a second opinion, let alone several. ASignal runs TCRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.